Results 61 to 70 of about 20,678 (258)

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials

Frontiers in Endocrinology, 2020
The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the presence of nutrients in the small intestines.
Matthew P. Gilbert, Richard E. Pratley
doaj   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

Purification of Advanced Therapeutics by Flow‐Through Pseudo‐Affinity Chromatography: Bi‐Specific mABs, Fc Fusion Proteins, and Adeno‐Associated Viruses

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Modern biopharmaceutical manufacturing requires purification platforms capable of processing structurally and functionally diverse products while addressing the challenge of removing persistent and high‐risk host cell proteins (HCPs).
Wenning Chu, Eduardo Barbieri, Arianna Minzoni, Shriarjun Shastry, Jacob P. LeBarre, Qingbo Shu, Taufika Williams, Xuanwen Li, Divya Chandra, Xuankuo Xu, Jerome Bill, David Roush, Joseph Taris, Patrick Gilbert, Andre Kiesewetter, Oliver Rammo, Michael Schulte, Christopher Major, Trina Mouchahoir, Steven Cramer, Cristiana Boi, Ruben G. Carbonell, Abraham Lenhoff, Stefano Menegatti   +23 more
wiley   +1 more source

Atomically precise metal cluster enzymes for pathological tissue regeneration

BMEMat, EarlyView.
Schematic illustration of atomically precise metal cluster enzymes (MCEs) for pathological tissue regeneration. Atomically precise MCEs can modulate biological processes, such as attenuation of inflammatory responses, eradication of bacterial pathogens, regulation of angiogenesis, and promotion of cell development.
Ziqiang Xiong, Zhifeng Shi, Mengqing Li, Jien Han, Haoyan Chen, Maofei Ran, Shaojian Zhong, Limin Ma, Chengyun Ning, Youzhun Fan, Zhenghua Tang, Peng Yu   +11 more
wiley   +1 more source

Homologous tumor‐targeting biomimetic nanozyme for synergistic NIR‐II photothermal and chemodynamic therapy

BMEMat, EarlyView.
Studies reveal that a biomimetic nanoplatform based on a cancer cell membrane‐camouflaged Au‐MnOx nanozyme (Au‐MnOx@CCM) can achieve synergistic antitumor therapy by combining NIR‐II mediated PTT with enhanced CDT, offering a promising strategy for precise and efficient tumor therapy. Abstract The therapeutic potential of nanozyme‐mediated chemodynamic
Xiaonan Li, Siman Luo, Yucheng Zuo, Liheng Chen, Houjuan Zhu, Jing‐Yi Zhu, Wei Xue   +6 more
wiley   +1 more source

Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria

International Journal of Endocrinology, 2013
Incretin-based therapies represent one of the most promising options in type 2 diabetes treatment owing to their good effectiveness with low risk of hypoglycemia and no weight gain. Other numerous potential beneficial effects of incretin-based therapies
Martin Haluzík, Jan Frolík, Ivan Rychlík   +2 more
doaj   +1 more source

Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing

BMC Geriatrics, 2017
Background Preventable drug-related hospital admissions can be associated with drugs used in diabetes and the benefits of strict diabetes control may not outweigh the risks, especially in older populations.
Gisela Schott, Yolanda V Martinez, R. Erandie Ediriweera de Silva, Anna Renom-Guiteras, Anna Vögele, David Reeves, Ilkka Kunnamo, Minna Marttila-Vaara, Andreas Sönnichsen   +8 more
doaj   +1 more source

GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance

Chronic Diseases and Translational Medicine, EarlyView.
Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig, Jason Ta, Sophie Jones, Emily Scott, Khalid Sofi, Frances Osler, Marije Jansen, Puneet Chhabra   +7 more
wiley   +1 more source